Combining BAY3498264 with Sotorasib for Advanced Solid Cancers with KRAS G12C Mutation

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the safety and efficacy of BAY3498264 when administered alongside Sotorasib in patients with advanced solid tumors harboring the KRAS G12C mutation. Sotorasib is an approved treatment that targets cancer cells with this specific mutation, but its effectiveness can diminish over time. BAY3498264, currently in development, aims to enhance the effects of Sotorasib by inhibiting the SOS1 protein, potentially leading to improved treatment outcomes. The study will assess how well these two drugs work together in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed solid tumor malignancy with documented KRAS\^G12C mutation as assessed by an appropriately accredited laboratory.
* Documented disease progression after treatment with at least 1 prior standard of care (SoC) systemic therapy other than a G12C inhibitor for locally advanced or metastatic disease, and with no further standard treatment options available, or when standard treatment options are not acceptable and this study is a reasonable option.

  * Participants whose access to SoC therapies is limited due to regional access, refusal, intolerance, or eligibility may participate.
  * Prior G12C inhibitor treatment is permitted. Participants receiving prior G12C inhibitor therapy must have documented disease progression after treatment, or have discontinued that treatment due to intolerance.
* Adequate archival formalin-fixed paraffin-embedded tumor tissue available (preferably no older than 6 months, obtained after the last targeted therapy). If archival material is not available, a fresh tumor biopsy should ideally be obtained if safe and feasible.
* Eastern Cooperative Oncology Group (ECOG) of 0 to 2 and life expectancy of at least 12 weeks.

Exclusion Criteria:

\- Active central nervous system (CNS) tumors including metastatic brain disease, at the time of screening.

1. 'Active' is defined as untreated brain lesions (new or progressing) or symptomatic brain lesions (as determined by the investigator).
2. Participants who have received treatment (e.g. surgery or radiotherapy) for brain metastases ending at least 4 weeks before the start of study intervention may be eligible if, at the point of study entry:

i. their condition is considered stable by the investigator. ii. they have no residual neurological symptoms (Grade \>2). iii. a follow-up Magnetic resonance imaging (MRI) scan during the screening period shows no progression or new lesions.

iv. they do not need systemic corticosteroids to treat symptoms of brain metastasis.

* Any grade active pneumonitis or interstitial lung disease (ILD), or past medical history of:

  1. Grade ≥2 ILD,
  2. Drug-induced ILD,
  3. Radiation pneumonitis that required steroid treatment within the last 12 months.
* Additional malignancy within the past 3 years, except for basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, superficial bladder tumors, localized prostate cancer or other tumors that in the opinion of the investigator, in agreement with the Sponsor, are considered cured or not immediately life-threatening, and will not interfere with the scientific goals of this study.
* Any positive test result for hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating the presence of virus.

  * Active HBV (chronic or acute; defined as having a known positive HBsAg test at the time of screening) except for participants on antiviral therapy for HBV with an undetectable or low viral load.
  * Participants with past HBV infection or resolved HBV infection (defined as the presence of HBcAb and absence of HBsAg) are eligible if HBV DNA is negative.
  * Participants positive for HCV antibody unless polymerase chain reaction is negative for HCV RNA. Any prior antiviral therapy must be completed at least 28 days before the first dose of study intervention.

Where it's running

• Border Medical oncology - Albury Wodonga Regional Cancer Centre
  Albury, New South Wales, Australia Recruiting
• Macquarie University Hospital - Oncology Department
  Macquarie Park, New South Wales, Australia Recruiting
• Peninsula and Southeast Oncology
  Frankston, Victoria, Australia Recruiting
• Rigshospitalet Copenhagen University Hospital | Oncology Department
  Copenhagen, Capital Region / Region Hovedstaden, Denmark Recruiting
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS - UOC Oncologia Medica
  Rome, Lazio, Italy Recruiting
• Humanitas Mirasole S.p.A. - Oncologia Medica ed Ematologia
  Rozzano, Lombardy, Italy Recruiting

Study contacts

• Study coordinator: Bayer Clinical Trials Contact
• Email: clinical-trials-contact@bayer.com
• Phone: 0018888422937

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Acoramidis in adults with transthyretin amyloid cardiomyopathy in France

  This is an observational study to see how acoramidis is used in everyday care for adults with ATTR‑CM in France and how it affects their quality of life and daily function.

  Recruiting Bayer · Many Locations · NCT07791160

• How your body handles two forms of elinzanetant in healthy women

  This study tests whether a new tablet form of elinzanetant is absorbed and processed by the bodies of healthy women in the same way as an existing capsule form.

  Recruiting Phase 1 Bayer · Mount Royal, Quebec · NCT07762287

• Heart-risk in older men with advanced prostate cancer treated with enzalutamide or darolutamide

  This observational study tests whether heart-related risks differ for older men with advanced prostate cancer treated with enzalutamide or darolutamide.

  Recruiting Bayer · Whippany, New Jersey · NCT07672119

• How safe BAY3389934 is when given alone or with aspirin in healthy adults

  This study tests BAY3389934, alone and with aspirin, to see if it’s safe and how it affects blood clotting in healthy adults.

  Recruiting Phase 1 Bayer · Miami, Florida · NCT07652723

• BAY 3670549 in Atrial Fibrillation: Does it help restore normal rhythm after AF episode?

  This study tests BAY 3670549 against a placebo in adults with atrial fibrillation who need electrical cardioversion to see if it helps restore normal heart rhythm and how safe it is.

  Recruiting at 9 sites Phase 2 Bayer · San Francisco, California and 29 other locations · NCT07625215

• Finerenone in adults with CKD and type 2 diabetes in Spain: real-world changes in kidney risk score

  This observational study tests how finerenone affects a kidney-risk score in adults with CKD linked to type 2 diabetes who are already taking finerenone in routine care in Spain.

  Recruiting Bayer · Many Locations · NCT07554469

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.